Apoptin-modified human mesenchymal stem cells inhibit growth of lung carcinoma in nude mice

Du,Jingchun; Zhang,Yanling; Xu,Chun; Xu,Xia

doi:10.3892/mmr.2015.3501

Apoptin-modified human mesenchymal stem cells inhibit growth of lung carcinoma in nude mice

Authors:
- Jingchun Du
- Yanling Zhang
- Chun Xu
- Xia Xu
View Affiliations

Affiliations: Department of Laboratory Medicine, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China, Department of Laboratory Medicine, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China, Department of Clinical Immunology, School of Kingmed Diagnostics, Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/mmr.2015.3501
Pages: 1023-1029
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human mesenchymal stem cells (MSCs) represent a novel carrier for gene therapy and apoptin is a potential tumor‑selective apoptosis‑inducing protein. In the present study, the anti‑tumoral effect of MSCs modified with apoptin against lung carcinoma was evaluated. Apoptin protein was expressed in a prokaryotic expression system and purified by affinity chromatography. Subsequently, anti‑apoptin antibody was prepared by immunizing BALB/c mice with purified apoptin protein. Human MSCs were isolated, amplified and transduced with lentiviral vectors encoding full‑length apoptin, in which the secretory signal and protein transduction sequence were added into the amino terminus to assist apoptin in entering into target cells. The differentiation and apoptin expression of apoptin‑modified MSCs were confirmed. Subsequently, the anti‑tumor effect of apoptin‑modified MSCs was measured in vitro and in vivo. Following modification with apoptin, MSCs retained their differentiation capacity, and successfully synthesized and secreted apoptin, which entered target cells and selectively induced lung cancer cell apoptosis through activating caspase‑3. The percentage of tumor cells with activated caspase‑3 in the apoptin‑modified MSCs group was markedly higher than that in the MSCs group (16.5±2.9% at 24 h and 27.3±2.0% at 48 h vs. 3.4±1.1% at 24 h and 2.2±0.6% at 48 h). When injected into nude mice, apoptin‑modified MSCs inhibited the growth of lung carcinoma compared with that in the control groups (0.14±0.02 g vs. 0.21±0.04 g vs. 0.31±0.05 g, P<0.05). The results of the present study provided preclinical support of apoptin‑based cancer therapy with MSCs as cellular vehicles.

View Figures

View References

1	Cotrim AP and Baum BJ: Gene therapy: some history, applications, problems and prospects. Toxicol Pathol. 36:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
2	Verma IM and Somia N: Gene therapy – promise, problems and prospects. Nature. 389:239–242. 1997. View Article : Google Scholar : PubMed/NCBI
3	Lee RH, Kim B, Choi I, et al: Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem. 14:311–324. 2004. View Article : Google Scholar : PubMed/NCBI
4	Erices A, Conget P and Minguell JJ: Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 109:235–242. 2000. View Article : Google Scholar : PubMed/NCBI
5	Le Blanc K, Rasmusson I, Sundberg B, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363:1439–1441. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kidd S, Spaeth E, Dembinski JL, et al: Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 27:2614–2623. 2009. View Article : Google Scholar : PubMed/NCBI
7	Raper SE, Chirmule N, Lee FS, et al: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 80:148–158. 2003. View Article : Google Scholar : PubMed/NCBI
8	Msaouel P, Iankov ID, Dispenzieri A and Galanis E: Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol. 13:1732–1741. 2012. View Article : Google Scholar :
9	Kucerova L, Altanerova V, Matuskova M, Tyciakova S and Altaner C: Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 67:6304–6313. 2007. View Article : Google Scholar : PubMed/NCBI
10	Grisendi G, Bussolari R, Cafarelli L, et al: Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70:3718–3729. 2010. View Article : Google Scholar : PubMed/NCBI
11	Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T and Los M: Cancer- selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther. 5:10–19. 2006. View Article : Google Scholar : PubMed/NCBI
12	Backendorf C, Visser AE, de Boer AG, et al: Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol. 48:143–169. 2008. View Article : Google Scholar
13	Li X, Liu Y, Wen Z, et al: Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vitro. Mol Cancer. 9:102010. View Article : Google Scholar
14	Schoop RA, Baatenburg de Jong RJ and Noteborn MH: Apoptin induces apoptosis in an oral cancer mouse model. Cancer Biol Ther. 7:1368–1373. 2008. View Article : Google Scholar : PubMed/NCBI
15	Torchilin VP and Lukyanov AN: Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today. 8:259–266. 2003. View Article : Google Scholar : PubMed/NCBI
16	Du J, Zhou L, Chen X, et al: IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol. 44:1305–1314. 2012. View Article : Google Scholar : PubMed/NCBI
17	Aboody KS, Najbauer J and Danks MK: Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sun J, Yan Y, Wang XT, et al: PTD4-apoptin protein therapy inhibits tumor growth in vivo. Int J Cancer. 124:2973–2981. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kyriakou CA, Yong KL, Benjamin R, et al: Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFLk-1) following lentiviral-mediated gene transfer inhibit growth of burkitt’s lymphoma in a murine model. J Gene Med. 8:253–264. 2006. View Article : Google Scholar
20	Chang LJ and Gay EE: The molecular genetics of lentiviral vectors - current and future perspectives. Curr Gene Ther. 1:237–251. 2001. View Article : Google Scholar
21	Loebinger MR, Eddaoudi A, Davies D and Janes SM: Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 69:4134–4142. 2009. View Article : Google Scholar : PubMed/NCBI
22	Danen-Van Oorschot AA, Zhang YH, Leliveld SR, et al: Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem. 278:27729–27736. 2003. View Article : Google Scholar : PubMed/NCBI
23	Daugherty BL, Zavodny SM, Lenny AB, et al: The uses of computer-aided signal peptide selection and polymerase chain reaction in gene construction and expression of secreted proteins. DNA Cell Biol. 9:453–459. 1990. View Article : Google Scholar : PubMed/NCBI
24	Flinterman M, Farzaneh F, Habib N, Malik F, Gäken J and Tavassoli M: Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther. 17:334–342. 2009. View Article : Google Scholar
25	Danen-van Oorschot AA, van Der Eb AJ and Noteborn MH: The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol. 74:7072–7078. 2000. View Article : Google Scholar : PubMed/NCBI
26	Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S and Los M: Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci. 118:4485–4493. 2005. View Article : Google Scholar : PubMed/NCBI
27	Zhu W, Xu W, Jiang R, et al: Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 80:267–274. 2006. View Article : Google Scholar